Association of < em > CYP3A5*3, CYP3A4*18 & amp; CYP2B6*6 < /em > polymorphisms with imatinib treatment outcome in Azerbaijani chronic myeloid leukaemia patients
CONCLUSIONS: Our results demonstrated that CYP3A4*18 was significantly associated with IM treatment response in patients with CML in Azerbaijan, whereas rather common CYP3A5*3 was identified to have no such association.PMID:37706370 | DOI:10.4103/ijmr.ijmr_1103_22
Source: The Indian Journal of Medical Research - Category: Biomedical Science Authors: Chingiz Asadov Nigar Karimova Aypara Hasanova Bayram Bayramov Aytan Shirinova Zohra Alimirzoyeva Source Type: research
More News: Azerbaijan Health | Biomedical Science | Chronic Leukemia | Chronic Myeloid Leukaemia | Genetics | Gleevec | India Health | Leukemia | Research